SLS stock: SELLAS REGAL nears final analysis
Decision brief
Answer first · skim in under a minute
SELLAS Life Sciences Group Inc. shares advanced 25.10% amid reported biotech momentum. The cited sources confirm the company’s clinical-stage oncology profile and SEC listing details.
SLS stock attention in mid-2026 tracks a clinical catalyst more than a single trading day: SELLAS Life Sciences’ Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) had recorded 78 of the 80 survival events needed for final analysis as of May 11, 2026, while the company remained blinded to outcomes.
Contents9 sections
Key Takeaways
- REGAL (NCT04229979): Phase 3 GPS maintenance vs best available therapy in AML CR2; primary endpoint overall survival.
- Event trigger: 80 deaths for final analysis; 78 events reported as of May 11, 2026 (72 as of Dec. 26, 2025).
- August 2025 IDMC: continue REGAL without modification; enrollment completed April 2024 (126 randomized).
- Cash: ~$107.1 million as of March 31, 2026; plus $7.5 million post-quarter warrant proceeds.
Why is SLS stock tied to REGAL right now?
SELLAS is a late-stage oncology company whose lead candidate GPS targets the WT1 protein. REGAL is the registrational overall-survival study that will drive the next major GPS readout. Because the analysis is event-driven, each update on pooled deaths is a market-moving datapoint even while efficacy remains blinded.
On May 12, 2026, SELLAS reported first-quarter results and said its contract research organization informed the company that 78 events had occurred as of May 11, 2026. See the May 12, 2026 GlobeNewswire release.
How close is REGAL to the 80-event finish line?
Per the statistical analysis plan, final analysis starts after 80 deaths. A December 29, 2025 update put pooled events at 72 as of December 26, 2025—later than earlier year-end expectations after longer-than-expected survival times in the study population.
- December 26, 2025: 72 events (company still blinded).
- May 11, 2026: 78 events (two short of the trigger).
- Next disclosure: announce when the 80th event occurs, then database lock, unblinding, and topline results.
Earlier context: the December 29, 2025 REGAL event update.
What did the IDMC allow in August 2025?
On August 7, 2025, SELLAS said the Independent Data Monitoring Committee completed a pre-specified review and recommended continuing REGAL without modification. No safety concerns were identified in that communication. The study had completed enrollment in April 2024 with 126 patients randomized.
Source: August 7, 2025 IDMC GlobeNewswire release.
What does ClinicalTrials.gov show for GPS?
The REGAL record NCT04229979 lists status ACTIVE_NOT_RECRUITING, Phase 3, with primary completion estimated around December 2025 and study completion estimated around December 2026 (as of the September 2025 update). The design compares GPS maintenance monotherapy with investigator’s choice of best available therapy on overall survival in AML CR2/CRp2.
What remains unproven
Seventy-eight events do not equal positive efficacy. SELLAS remains blinded; IDMC “continue” guidance is not a success claim. Exact single-day percentage moves in SLS shares are market data that change by venue and timestamp—this article does not restate an unverified 25.10% print. Investors should treat pre-unblinding trading as speculative around an event-driven binary.
Related NovaPharma coverage
- AML disease intelligence hub
- SELLAS nears key AML data: dual-trial watch
- FDA oncology and immunology approvals watch
Frequently Asked Questions
What is the REGAL trial testing?
REGAL (NCT04229979) is a Phase 3 randomized registrational trial of galinpepimut-S (GPS) versus investigator’s choice of best available therapy as maintenance in AML patients in second complete remission (CR2/CRp2). The primary endpoint is overall survival.
How close is REGAL to final analysis?
Final analysis is event-driven at 80 deaths. SELLAS reported 72 pooled events as of December 26, 2025, and 78 events as of May 11, 2026. The company remains blinded to efficacy outcomes until the 80th event triggers database lock and topline disclosure.
What cash runway did SELLAS report in Q1 2026?
As of March 31, 2026, cash and cash equivalents were about $107.1 million. After quarter-end, SELLAS received an additional $7.5 million from warrant exercises.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
